Trial finds cannabidiol no better than placebo for severe behavioural problems in young people with intellectual disability
A randomised controlled trial published in JAMA Pediatrics found cannabidiol was no more effective than placebo for severe behavioural problems in young people with intellectual disability.
Research Digest
A randomised controlled trial published in the journal JAMA Pediatrics on 16 November 2026 found that cannabidiol (CBD) did not reduce severe behavioural problems in children and adolescents with intellectual disability more than a placebo did. The paper is a journal article, not a preprint.
According to the paper, the double-blind trial ran at three Australian children’s hospitals. It randomised 131 participants aged 6 to 18 to a purified CBD isolate in oil (10 mg per kg of body weight per day) or a placebo for eight weeks. Most participants (84 per cent) also had autism.
The study found that parent-reported irritability scores after eight weeks were similar in the two groups: the mean difference was 2.4 points on the irritability subscale of the Aberrant Behavior Checklist (95% confidence interval −1.5 to 6.3). At least one adverse event was reported by 63.1 per cent of the CBD group and 60.6 per cent of the placebo group.
The trial’s ClinicalTrials.gov record shows it was registered in March 2021, began in May 2021 and was completed in August 2025, with no results posted on the registry. The paper appeared about 15 months after completion, more than five and a half years after registration. The record also lists an earlier pilot trial, published in 2021.
The authors concluded that “CBD was not effective in treating severe behavioral problems in youths with intellectual disability.”
Source: JAMA Pediatrics — Cannabidiol for Severe Behavioral Problems in Youths With Intellectual Disability: A Randomized Clinical Trial (published 16 November 2026; DOI 10.1001/jamapediatrics.2026.5152)
Trial registration: ClinicalTrials.gov NCT04821856 (record last updated 3 September 2025; read 18 November 2026)